Uncategorised - European Medical Journal

EMJ's Latest Hematology Journal

Featuring exclusive coverage of the EHA 2025 Congress, uncover industry insights from leading experts, the current treatment landscape for…

CLL Highlights from EHA 2025

This review article explores key research highlights and new data on CLL presented at EHA 2025, considering how the latest clinical…

Gene Therapy: Living With(out) Haemophilia?

Since research on human gene therapy began, the expectations regarding its potential in treating haemophilia have been high. Haemophilia…

PPM1D Mutations in Patients with Clonal Haematopoiesis and Clonal Cytopenias

TP53 and PPM1D are key regulators of DNA damage response and repair, and somatic mutations in these genes often…

Ranking Treatments for Lenalidomide-Refractory Multiple Myeloma post DRd

Multiple myeloma is the second most common haematological malignancy, with an increasing global incidence…

Review of the European Hematology Association (EHA) 2025 Congress

THE 30ᵗʰ EUROPEAN Hematology Association (EHA) Congress was held in the beautiful city of Milan, Italy from the 12ᵗʰ–15ᵗʰ of June 2025…

Prognostic Assessment in AL Amyloidosis

Systemic light chain (AL) amyloidosis is a rare plasma cell dyscrasia characterised by the extracellular deposition of misfolded Ig light…

Re-evaluating European Haemophilia Standards

TEST In this feature, the authors critically analyse the European standards for Haemophilia Treatment Centres (HTC), examining their…

Hydroxyurea and Gut Function in Sickle Cell Disease Mice

Sickle cell disease (SCD) is a genetic disorder characterised by chronic inflammation, vaso-occlusion, and endothelial…

The Immunotherapy Landscape for Multiple Myeloma

Take a look at our latest haematology infographic, which explores the current immunotherapy treatment landscape for multiple myeloma…